Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AVR vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)

AVR Overall Winner 6-Pillar Tally: AVR 3 – 2 BMRA (1 Tie) Matrix Metrics: AVR 5 – 3 BMRA

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AVR carries a Unified Composite Score of 41.2/100 (SELL) at $5.59 (N/M Forward P/E, -4880.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. AVR 41.2/100 SELL), AVR captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-4880.4% vs. -125.2% operating margin) and revenue trajectory (+21.0% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVR vs BMRA
AVR NASDAQ Head-to-Head Winner
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$5.59
+3.23% 1D
Market Cap $570.4M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.57β · 76% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 31.0 Fund 49.0 Flow 57.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $5.92 · SMA50: $6.89
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (AVR 3 – 2 BMRA)

Columns: Metric · AVR · BMRA
1. Valuation Multiples BMRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.1x
2. Growth & Scale AVR
Revenue Growth (YoY) +21.0% -8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $4.3M
Market Cap $570.4M $6.0M
3. Profitability & Quality AVR
Gross Margin 75.8% 0.9%
Operating Margin -4880.4% -125.2%
Net Profit Margin 0.0% -115.5%
Return on Equity (ROE) -93.3% -113.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$94M -$3.2M
Cash Flow Margin N/A -73.5%
Net Cash / Leverage $216M Net Cash $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 58.5% (52nd %ile) N/A (N/A)
Put/Call OI Skew 0.66x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVR (5) vs BMRA (3)
Institutional Metric AVR BMRA Criterion Row Edge
Market Capitalization
Scale
$570.4M $6.0M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+21.0% -8.3% Higher Growth AVR
Operating Margin (TTM)
Profitability
-4880.4% -125.2% Higher Margin BMRA
Net Profit Margin
Profitability
0.0% -115.5% Higher Margin AVR
Return on Equity (ROE)
Capital Efficiency
-93.3% -113.8% Higher ROE AVR
52-Week Range Position
Momentum
30% ($3–$11) 4% ($1–$3) Stronger Trend AVR
Beta / 30D Volatility
Risk Regime
1.57β · 76% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$94M ($216M Net Cash) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVR +20.67 pp
AVR: -7.52% · BMRA: -28.19%
3M Horizon BMRA +24.63 pp
AVR: -41.6% · BMRA: -16.97%
6M Horizon AVR +14.87 pp
AVR: -26.09% · BMRA: -40.96%
1Y Horizon AVR +94.49 pp
AVR: +47.63% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AVR Revenue BMRA Revenue AVR Op. Margin BMRA Op. Margin Margin Leader
FY2019 N/A $10M N/A -46.4% BMRA
FY2020 N/A $10M N/A -41.0% BMRA
FY2021 N/A $10M N/A -104.2% BMRA
FY2022 N/A $20M N/A -24.0% BMRA
FY2023 N/A $10M N/A -135.3% BMRA
FY2024 $0M $10M -2899.4% -117.6% BMRA
FY2025 $0M $10M -4908.2% -96.7% BMRA
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVR BREAKDOWN
101d in phase · OBV NEUTRAL
Current IV 58.5%
IV Percentile 52nd %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $570.4M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVR vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AVR carries a Unified Composite Score of 41.2/100 (SELL) at $5.59 (N/M Forward P/E, -4880.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. AVR 41.2/100 SELL), AVR captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-4880.4% vs. -125.2% operating margin) and revenue trajectory (+21.0% vs. -8.3% YoY). Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVR leads the Growth & Scale pillar: AVR posts +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AVR cumulative revenue shifted N/A while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, AVR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

BMRA screens cheaper on headline valuation multiples. AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVR (-93.3% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AVR carries 58.5% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 76% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.